UNLIMITED TURBO LONG - ELI LILLY & CO | Market Closed - Borsa Italiana 15:59:51 2024-06-21 EDT | ||
| 14.02 EUR | +0.07% |
|
| Current month | +71.27% | ||
| 1 month | +103.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-06-21 | 14.01 | 0.00% |
| 24-06-20 | 14.01 | -6.16% |
| 24-06-19 | 14.93 | +2.68% |
| 24-06-18 | 14.54 | +3.71% |
| 24-06-17 | 14.02 | +5.10% |
Real-time Borsa Italiana
Last update June 21, 2024 at 03:59 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| P232Z1 | |
| ISIN | NLBNPIT232Z1 |
| Date issued | 2024-05-17 |
| Strike | 757.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.73 € |
|---|---|
| Lowest since issue | 3.52 € |
| Spread | 0.3 € |
| Spread % | 2.12% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
883.9
USD
Average target price
855.4
USD
Spread / Average Target
-3.22%
- Stock Market
- Certificates
- P232Z1 Certificat
